SCHEMBL5525931

SCHEMBL5525931

CCN(CC)Cc1ccc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CCN(c5cccc(Cl)c5)CC4)c(OC(F)(F)F)c32)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
PIM1 P11309 1/20 0.39
TOP1 P11387 7/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.37
PIK3CD O00329 1/20 0.37
PIK3R1 P27986 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37
POLB P06746 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TOP2A P11388 1/20 0.36
MAPT P10636 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5531014 0.94 HPGD (0.44) HPGDHSD17B10TOP1MEN1LMNA
SCHEMBL5523036 0.93 HPGD (0.41) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5526300 0.92 TOP1 (0.47) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5531068 0.90 PIK3CD (0.40) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5530834 0.89 KDM4E (0.43) HPGDHSD17B10TOP1MEN1LMNA
SCHEMBL5523908 0.89 PIM1 (0.43) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5531448 0.88 HPGD (0.43) HPGDHSD17B10PIM1TOP1LMNA
SCHEMBL5525045 0.86 LMNA (0.47) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5530221 0.86 LMNA (0.45) HPGDHSD17B10PIM1TOP1MEN1
SCHEMBL5531276 0.86 HPGD (0.39) HPGDHSD17B10TOP1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US claimed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions TP53, RB1, HRAS HPGD 150/4885HSD17B10 663/4885PIM1 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.